Education
About Us
Working with TipRanks
Follow Us
CombiGene AB (SE:LARK)
:LARK
Total Valuation
CombiGene AB has a market cap or net worth of kr42.57M. The enterprise value is -kr30.78M.
Market Capkr42.57M
Enterprise Value-kr30.78M
Share Statistics
CombiGene AB has 19,801,197 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding19,801,197
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
CombiGene AB’s return on equity (ROE) is -0.63 and return on invested capital (ROIC) is -65.97%.
Return on Equity (ROE)-0.63
Return on Assets (ROA)-0.59
Return on Invested Capital (ROIC)-65.97%
Return on Capital Employed (ROCE)-0.66
Revenue Per Employee326.00K
Profits Per Employee0.00
Employee Count1
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of CombiGene AB is ―. CombiGene AB’s PEG ratio is -0.04.
PE Ratio―
PS Ratio144.56
PB Ratio0.66
Price to Fair Value0.66
Price to FCF-1.57
Price to Operating Cash Flow-3.50
PEG Ratio-0.04
Income Statement
In the last 12 months, CombiGene AB had revenue of 326.00K and earned -44.88M in profits. Earnings per share was -2.27.
Revenue326.00K
Gross Profit-46.78M
Operating Income-47.22M
Pretax Income-44.88M
Net Income-44.88M
EBITDA-34.22M
Earnings Per Share (EPS)-2.27
Cash Flow
In the last 12 months, operating cash flow was -29.95M and capital expenditures 0.00, giving a free cash flow of -29.95M billion.
Operating Cash Flow-29.95M
Free Cash Flow-29.95M
Free Cash Flow per Share-1.51
Dividends & Yields
CombiGene AB pays an annual dividend of kr1.93, resulting in a dividend yield of 8.47%
Dividend Per Sharekr1.93
Dividend Yield8.47%
Payout Ratio-144.25%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.04
52-Week Price Change-0.09%
50-Day Moving Average2.31
200-Day Moving Average2.37
Relative Strength Index (RSI)41.06
Average Volume (3m)41.41K
Important Dates
CombiGene AB upcoming earnings date is Feb 13, 2026, TBA (Confirmed).
Last Earnings DateNov 7, 2025
Next Earnings DateFeb 13, 2026
Ex-Dividend Date―
Financial Position
CombiGene AB as a current ratio of 17.47, with Debt / Equity ratio of 0.00%
Current Ratio17.47
Quick Ratio17.47
Debt to Market Cap0.00
Net Debt to EBITDA2.16
Interest Coverage Ratio0.00
Taxes
In the past 12 months, CombiGene AB has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
CombiGene AB EV to EBITDA ratio is 0.78, with an EV/FCF ratio of 0.89.
EV to Sales-81.66
EV to EBITDA0.78
EV to Free Cash Flow0.89
EV to Operating Cash Flow0.89
Balance Sheet
CombiGene AB has kr73.75M in cash and marketable securities with kr0.00 in debt, giving a net cash position of kr73.75M billion.
Cash & Marketable Securitieskr73.75M
Total Debtkr0.00
Net Cashkr73.75M
Net Cash Per Sharekr3.72
Tangible Book Value Per Sharekr3.61
Margins
Gross margin is 0.00%, with operating margin of -14484.05%, and net profit margin of -13766.26%.
Gross Margin0.00%
Operating Margin-14484.05%
Pretax Margin-13766.26%
Net Profit Margin-13766.26%
EBITDA Margin-10496.93%
EBIT Margin-14484.05%
Analyst Forecast
The average price target for CombiGene AB is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast-94.12%
EPS Growth Forecast-25.83%